Company / R&D Expense
Envista Holdings R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$114.0M
FY2025
5-year range
$93.8M / $114.0M
FY2021-FY2025
Trend
+15.0%
vs FY2024
Sector context
#50 of 105
Health Care
What the data says
At $114M, Envista Holdings's r&d expense ranks #50 of 105 in the Health Care sector. R&D Expense has fluctuated over the past 9 years, ranging from $87M in FY2020 to $172M in FY2017.
Based on SEC 10-K filings.
$114M in FY2025 with a 5-year CAGR of +5.6%.
Improved from $94M to $114M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +4.4%
- 5-Year CAGR
- +5.6%
- 10-Year CAGR
- -
Sector benchmark
#50 of 105 in Health CareTop 48% of 105This company $114.0M Sector average $284.2M
▼
-59.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.6%, indicating consistent growth.
- In FY2025, r&d expense increased 15.0% year-over-year.
- Ranks #50 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.0M | +15.0% |
| FY2024 | $99.1M | +5.7% |
| FY2023 | $93.8M | -6.3% |
| FY2022 | $100.1M | -0.4% |
| FY2021 | $100.5M | +15.9% |
| FY2020 | $86.7M | -34.9% |
| FY2019 | $133.1M | -22.6% |
| FY2018 | $172.0M | -0.2% |
| FY2017 | $172.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026